Zika virus, a mosquito-borne flavivirus, was first isolated from a febrile macaque in the Zika forest of Uganda. Up until 2013 there were only small sporadic outbreaks of Zika and it was described as causing a mild illness with only about 20% of infected individuals presenting for care. The first large outbreak occurred in French Polynesia in 2013. In 2015, a large outbreak started in Brazil and, since that time, has spread voraciously throughout South and Central America. In the fall of 2015 Brazil reported an increasing incidence of microcephaly that was thought to be due to Zika infection and the WHO declared Zika virus and its association with microcephaly a Pandemic of Health Emergency of International Concern. In April, 2016 the U.S. CDC confirmed the link between Zika virus infection of pregnant women and microcephaly in the fetus. To address the severe complication of microcephaly caused by Zika virus, many groups and manufacturers have committed to developing a Zika virus vaccine. The landscape of Zika virus vaccine development and the strategies for evaluation and deployment will be discussed.